Overactive Bladder - Results from #540

Patient Perceptions Impact Progression to Third Line Therapy for Treatment of Overactive Bladder. July 4, 2021

Axonics® System for Treatment of Overactive Bladder Syndrome and Urinary Urgency Incontinence. July 4, 2021

Do we need more patient-friendly treatment options for overactive bladder (OAB)? June 27, 2021

Transcutaneous electrical nerve stimulation and solifenacin succinate versus solifenacin succinate alone for treatment of overactive bladder syndrome: A double-blind randomized controlled study. June 27, 2021

Overactive bladder phenotypes: development and preliminary data. June 20, 2021

Gene Therapy for Overactive Bladder: A Review of BK-Channel α-Subunit Gene Transfer. June 13, 2021

Mirabegron versus Solifenacin in Children with Overactive Bladder: Prospective Randomized Single-Blind Controlled Trial. June 13, 2021

Laparoscopic removal of intravesically inserted transobturator tape. June 13, 2021

Cost-Effectiveness Analysis Between Sacral Neuromodulation and OnabotulinumtoxinA for the Treatment of Refractory Overactive Bladder in Women: A Systematic Review. June 6, 2021

Population-Based Study of Prevalence, Bother and Behavior Related to Treatment for Lower Urinary Tract Symptoms and Overactive Bladder among Polish Neurogenic Patients. June 6, 2021

What are the chances of improvement or cure from overactive bladder? A pooled responder analysis of efficacy and treatment emergent adverse events following treatment with fesoterodine. May 30, 2021

Urodynamic and clinical features in women with overactive bladder: When to suspect concomitant voiding dysfunction? May 30, 2021

FDA Clearance of Uro-G Cystoscope Completes Suite of Portable, Single-Use, Disposable Cystoscopes May 24, 2021

Treatment for overactive bladder: A meta-analysis of transcutaneous tibial nerve stimulation versus percutaneous tibial nerve stimulation. May 23, 2021

Effects of overactive bladder syndrome on female sexual function. May 23, 2021

Is a 50% improvement threshold adequate to justify progression from sacral neuromodulation testing to implant? May 23, 2021

Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study. May 16, 2021

Protocol for development and validation of a prediction model for 5-year risk of incident overactive bladder in the general population: the Nagahama study. May 16, 2021

Adding mirabegron after intravesical onabotulinumtoxinA injection improves therapeutic effects in patients with refractory overactive bladder. May 9, 2021

[Functional results and satisfaction in 44 patients after implantation of a NS3-type sacral neurostimulator for refractory idiopathic overactive bladder followed at 43 months, single-center series]. May 9, 2021

Page 28 of 122